Stocks · News reference

Jupiter Neurosciences shares are trading higher after the company announced the first patient has been dosed in its Phase 2a RESET clinical trial evaluating JOTROL in patients with Parkinson’s disease.

Oct 6, 2026, 6:26 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 6, 2026, 3:18 PMBenzinga Newsdesk
Jupiter Neurosciences Doses First Participant In Its Phase 2a RESET Clinical Study Of JOTROL To Treat Parkinson's Disease
Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage biopharmaceutical company developing investigational therapies for neurodegenerative diseases, today announced that the first patient has been dosed in the
JUNS
SEC EDGARSep 3, 2026, 12:00 PMSEC EDGAR
8-K filing — JUPITER NEUROSCIENCES, INC. (JUNS)
Filed: 2026-09-03 AccNo: 0001493152-26-041315 Size: 212 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
JUNS
BenzingaAug 31, 2026, 2:14 PMAvi Kapoor
Dow Falls Over 300 Points; SAIC Shares Jump After Upbeat Q2 Results
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 300 points on Monday. Following the market opening Monday, the Dow traded down 0.61% to 53,232.50 while the NASDAQ slipped 0.45% to
CLGN FNGR JUNS SAIC VVOS